Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Exendin-(9-39), an antagonist of the
glucagon-like peptide-1 (GLP-1) receptor with effects on the pancreatic beta cell, increases
fasting blood glucose levels in subjects with congenital hyperinsulinism.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Diva De Leon
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH)